Program overview
Context
Indication: Non-Small-Cell Lung Carcinoma
Mechanism: Unknown
Modality: Unknown
Sponsor: Holy Cross Hospital, Florida
Registry Stop Signal
Belinostat, carboplatin, paclitaxel and bevacizumab
Belinostat, carboplatin, paclitaxel and bevacizumab is flagged as registry stop signal because public records show a registry stop signal. This is a public-data monitoring signal, not a conclusion about clinical failure, regulatory noncompliance, or sponsor intent.
Scores
Risk-signal summary
Registry: 5/5
Timeline: 1/5
Recruitment burden: 1/5
Results availability: 0/5
Program risk: 4/5
Evidence
Public links
https://clinicaltrials.gov/study/NCT01090830
Linked trials
Trial-level signal details
| Trial | Status | Timeline | Results | Burden |
|---|---|---|---|---|
| NCT01090830 | Registry Stop Signal (TERMINATED) | stale_update_signal | Low Signal | strict_eligibility_signal |